Company profile
Panacea Life Sciences Holdings, Inc.
OTC: PLSH · Healthcare · Drug Manufacturers - Specialty & Generic
#777 of 1,418 Healthcare companies by revenuetop-quartile growth
EA Score
——FH —DQ 38GM —SS 19
v0.1 · 25/100 weight · pillars only
↑ revenue growth (YoY), disclosure history · ↓ workforce scale, listing tenure
Methodology →Revenue TTM
$263.9k
Rev growth YoY (TTM)
-90.2%
Net income (FY)
-$8.0M
Employees
3
as of 2026-08-25
Market cap
$2.0M
as of 2026-08-25
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$2.4M$2.4M2023
Net income-$8.0M-$8.0M2023
Operating income-$5.5M-$5.5M2023
Total assets$18.0M$18.0M2023
Liabilities$26.3M$26.3M2023
Equity-$8.3M-$8.3M2023
Revenue trend
FY2018 – FY2023 · USD
FY18
FY20
FY19
FY20
FY20
FY22
FY22
FY23
Revenue by segment
No segmentation disclosed for this filer. n/a
The read
What is Panacea Life Sciences Holdings, Inc.’s revenue?
Panacea Life Sciences Holdings, Inc. booked $2.4M in FY2023 revenue, growing 47% year over year — faster than most Healthcare companies we track, at a -336.1% net margin.
Peers · Healthcare
Lattice Biologics Ltd.——Quantum-Si incorporated40DDNAPrint Genomics, Inc.——Perimeter Medical Imaging AI, Inc.39DElicio Therapeutics, Inc.24DFemasys Inc.41DNeighbors
Arapahoe →Key facts
CEOLeslie A. Buttorff
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
HeadquartersGreenwood Village, CO
ExchangeOTC: PLSH
Employees3
IPO date2022-04-04
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.